Lamotrigine (All indications)

Neonatal disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15218
R62394		 Bromley (Lamotrigine) (Epilepsy), 2023 Neonatal complications during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 1.20 [0.58;2.48] C 23/106   15/80 38 106
ref
S8978
R30435		 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Neonatal condition during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.95 [0.85;1.06] C 349/2,813   221,770/1,707,707 222,119 2,813
ref
Total 2 studies 0.95 [0.85;1.07] 222,157 2,919
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bromley (Lamotrigine) (Epilepsy), 2023Bromley, 2023 1 1.20[0.58; 2.48]381062%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: low Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Coste, 2020 2 0.95[0.85; 1.06]222,1192,81398%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 0.95[0.85; 1.07]222,1572,9190.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Epilepsy; 2: Lamotrigine) (Controls unexposed NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.95[0.85; 1.07]222,1572,9190%NABromley (Lamotrigine) (Epilepsy), 2023 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.95[0.85; 1.06]222,1192,813 -NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 1.20[0.58; 2.48]38106 -NABromley (Lamotrigine) (Epilepsy), 2023 1 Tags Adjustment   - No  - No 0.95[0.85; 1.07]222,1572,9190%NABromley (Lamotrigine) (Epilepsy), 2023 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 2 All studiesAll studies 0.95[0.85; 1.07]222,1572,9190%NABromley (Lamotrigine) (Epilepsy), 2023 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.95[0.85; 1.06]222,1192,813 -NACoste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 1 unexposed, sick controlsunexposed, sick controls 1.20[0.58; 2.48]38106 -NABromley (Lamotrigine) (Epilepsy), 2023 10.510.01.0